会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
    • 用于产生由同型二聚体,同三聚体或二聚体二聚体和用途组成的稳定连接络合物的方法
    • US07550143B2
    • 2009-06-23
    • US11389358
    • 2006-03-24
    • Chien Hsing ChangDavid M. GoldenbergWilliam J. McBrideEdmund A. Rossi
    • Chien Hsing ChangDavid M. GoldenbergWilliam J. McBrideEdmund A. Rossi
    • C07K16/46C07K16/28C07K16/30A61K38/01A61K38/19A61K39/395
    • C12N9/12B82Y5/00B82Y10/00C07K16/18C07K16/2803C07K16/2887C07K16/3007C07K16/3092C07K2317/31C07K2317/55C07K2319/00C07K2319/70C12Y207/11011
    • The present invention concerns methods and compositions for stably tethered structures of defined compositions, which may have multiple functionalities and/or binding specificities. Particular embodiments concern homodimers comprising monomers that contain a dimerization and docking domain attached to a precursor. The precursors may be virtually any molecule or structure, such as antibodies, antibody fragments, antibody analogs or mimetics, aptamers, binding peptides, fragments of binding proteins, known ligands for proteins or other molecules, enzymes, detectable labels or tags, therapeutic agents, toxins, pharmaceuticals, cytokines, interleukins, interferons, radioisotopes, proteins, peptides, peptide mimetics, polynucleotides, RNAi, oligosaccharides, natural or synthetic polymeric substances, nanoparticles, quantum dots, organic or inorganic compounds, etc. Other embodiments concern tetramers comprising a first and second homodimer, which may be identical or different. The disclosed methods and compositions provide a facile and general way to obtain homodimers, homotetramers and heterotetramers of virtually any functionality and/or binding specificity.
    • 本发明涉及可以具有多种功能和/或结合特异性的限定组合物的稳定的束缚结构的方法和组合物。 具体实施方案涉及包含单体的同型二聚体,其含有连接到前体的二聚化和对接结构域。 前体实际上可以是任何分子或结构,例如抗体,抗体片段,抗体类似物或模拟物,适体,结合肽,结合蛋白的片段,蛋白质或其他分子的已知配体,酶,可检测标记或标签,治疗剂, 毒素,药物,细胞因子,白细胞介素,干扰素,放射性同位素,蛋白质,肽,肽模拟物,多核苷酸,RNAi,寡糖,天然或合成聚合物质,纳米颗粒,量子点,有机或无机化合物等。其他实施方案涉及四聚体, 和第二同二聚体,其可以相同或不同。 所公开的方法和组合物提供了获得实质上任何功能性和/或结合特异性的同源二聚体,同源四聚体和异源四聚体的简便且一般的方式。
    • 9. 发明申请
    • Inhibition of Placenta Growth Factor (PLGF) Mediated Metastasis and/or Angiogenesis
    • 抑制胎盘生长因子(PLGF)介导的转移和/或血管发生
    • US20100216662A1
    • 2010-08-26
    • US12620013
    • 2009-11-17
    • Alice P. TaylorDavid M. GoldenbergChien Hsing Chang
    • Alice P. TaylorDavid M. GoldenbergChien Hsing Chang
    • C40B30/04
    • C07K16/22A61K38/00C07K14/515Y02A50/491
    • The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (P1GF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more P1GF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The P1GF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, P1GF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, P1GF expression levels may be determined by any known method to select those patients most likely to respond to P1GF targeted therapies.
    • 本发明涉及用于抑制血管发生和/或肿瘤生长,存活和/或转移的方法和组合物。 在具体实施方案中,所述方法和组合物可以涉及针对胎盘生长因子(P1GF)的配体,例如BP-1,BP-2,BP-3或BP-4。 一些方法可以包括单独或与一种或多种其它试剂(例如化学治疗剂,其它抗血管生成剂,免疫治疗剂或放射免疫治疗剂)组合施用一种或多种P1GF配体。 P1GF配体有效抑制血管发生,肿瘤细胞运动,肿瘤转移,肿瘤生长和/或肿瘤存活。 在某些实施方案中,P1GF配体可以施用于受试者以改善其它血管生成相关病症,例如黄斑变性。 在一些实施方案中,P1GF表达水平可以通过任何已知方法来确定,以选择那些最有可能对P1GF靶向治疗作出反应的患者。
    • 10. 发明授权
    • Inhibition of placenta growth factor (PLGF) mediated metastasis and/or angiogenesis
    • 抑制胎盘生长因子(PLGF)介导的转移和/或血管发生
    • US07642239B2
    • 2010-01-05
    • US11581287
    • 2006-10-16
    • Alice P. TaylorDavid M. GoldenbergChien Hsing Chang
    • Alice P. TaylorDavid M. GoldenbergChien Hsing Chang
    • A61K38/04
    • C07K16/22A61K38/00C07K14/515Y02A50/491
    • The present invention concerns methods and compositions for inhibiting angiogenesis and/or tumor growth, survival and/or metastasis. In particular embodiments, the methods and compositions may concern ligands against placenta growth factor (PlGF), such as BP-1, BP-2, BP-3 or BP-4. Some methods may comprise administering one or more PlGF ligands, alone or in combination with one or more other agents, such as chemotherapeutic agents, other anti-angiogenic agents, immunotherapeutic agents or radioimmunotherapeutic agents to a subject. The PlGF ligands are effective to inhibit angiogenesis, tumor cell motility, tumor metastasis, tumor growth and/or tumor survival. In certain embodiments, PlGF ligands may be administered to subjects to ameliorate other angiogenesis related conditions, such as macular degeneration. In some embodiments, PlGF expression levels may be determined by any known method to select those patients most likely to respond to PlGF targeted therapies.
    • 本发明涉及用于抑制血管发生和/或肿瘤生长,存活和/或转移的方法和组合物。 在具体实施方案中,所述方法和组合物可涉及针对胎盘生长因子(PlGF)的配体,例如BP-1,BP-2,BP-3或BP-4。 一些方法可以包括单独或与一种或多种其它试剂(例如化学治疗剂,其它抗血管生成剂,免疫治疗剂或放射免疫治疗剂)组合施用一种或多种PlGF配体。 PlGF配体有效抑制血管生成,肿瘤细胞运动,肿瘤转移,肿瘤生长和/或肿瘤存活。 在某些实施方案中,可将PlGF配体施用于受试者以改善其它血管生成相关病症,例如黄斑变性。 在一些实施方案中,PlGF表达水平可以通过任何已知方法来确定,以选择那些最有可能对PlGF靶向治疗作出反应的患者。